Matches in SemOpenAlex for { <https://semopenalex.org/work/W4238956186> ?p ?o ?g. }
Showing items 1 to 47 of
47
with 100 items per page.
- W4238956186 endingPage "2" @default.
- W4238956186 startingPage "1" @default.
- W4238956186 abstract "Editorial ||FREE PAPER|| Garry M WalshAsthmatic and Allergic Inflammation Group, School of Medicine, University of Aberdeen, UKThis issue of Therapeutics and Clinical Risk Management contains two interesting and thorough review articles on the use of anti-tumor necrosis factor (TNF) monoclonal antibodies (mAb) in the treatment of rheumatoid arthritis and related disorders. The arthritic diseases and distressing conditions associated with significant morbidity are typified by reductions in functional capacity and quality of life with attendant substantial healthcare expenditure. Development of specifically targeted biological agents in recent years has greatly enhanced the therapeutic options for the treatment of the arthritic diseases such as rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. TNF is an attractive biological target as it has been implicated as a major pro-inflammatory player in a wide range of other conditions, in addition to the arthritic diseases, including inflammatory bowel disease (D’Haens and Daperno 2006), asthma (Cazzola and Polosa 2006), and other autoimmune diseases (Chatzantoni and Mozaki 2006). Levels of TNF are elevated in the relevant sites of inflammation in these conditions; eg, in the synovial fluid and sera of patients with active rheumatoid arthritis. TNF is a potent osteogenic cytokine and is the central mediator of inflammation and joint destruction in rheumatoid arthritis. Three TNF antagonists are currently available: infliximab, a chimeric anti-TNF mAb; adalimumab, a fully human anti-TNF mAb; and etanercept, a recombinant soluble p75 TNF-receptor-Fc fusion protein. Although there are no clinical studies that directly compare etanercept, infliximab, or adalimumab in the treatment of rheumatoid arthritis, data from noncomparative trials suggest that all have similar therapeutic efficacy." @default.
- W4238956186 created "2022-05-12" @default.
- W4238956186 creator A5024936437 @default.
- W4238956186 date "2007-02-01" @default.
- W4238956186 modified "2023-09-29" @default.
- W4238956186 title "Editorial" @default.
- W4238956186 cites W2055734184 @default.
- W4238956186 cites W2056493351 @default.
- W4238956186 cites W2069831315 @default.
- W4238956186 cites W2093510831 @default.
- W4238956186 cites W2126435265 @default.
- W4238956186 doi "https://doi.org/10.2147/tcrm.2007.3.1.1" @default.
- W4238956186 hasPublicationYear "2007" @default.
- W4238956186 type Work @default.
- W4238956186 citedByCount "8" @default.
- W4238956186 countsByYear W42389561862012 @default.
- W4238956186 countsByYear W42389561862013 @default.
- W4238956186 countsByYear W42389561862017 @default.
- W4238956186 countsByYear W42389561862018 @default.
- W4238956186 countsByYear W42389561862023 @default.
- W4238956186 crossrefType "journal-article" @default.
- W4238956186 hasAuthorship W4238956186A5024936437 @default.
- W4238956186 hasBestOaLocation W42389561861 @default.
- W4238956186 hasConcept C556039675 @default.
- W4238956186 hasConcept C71924100 @default.
- W4238956186 hasConceptScore W4238956186C556039675 @default.
- W4238956186 hasConceptScore W4238956186C71924100 @default.
- W4238956186 hasIssue "1" @default.
- W4238956186 hasLocation W42389561861 @default.
- W4238956186 hasOpenAccess W4238956186 @default.
- W4238956186 hasPrimaryLocation W42389561861 @default.
- W4238956186 hasRelatedWork W129828253 @default.
- W4238956186 hasRelatedWork W1505374175 @default.
- W4238956186 hasRelatedWork W1961603234 @default.
- W4238956186 hasRelatedWork W2013637744 @default.
- W4238956186 hasRelatedWork W2013915797 @default.
- W4238956186 hasRelatedWork W2033074403 @default.
- W4238956186 hasRelatedWork W2038285281 @default.
- W4238956186 hasRelatedWork W2280945256 @default.
- W4238956186 hasRelatedWork W2341235642 @default.
- W4238956186 hasRelatedWork W2408908265 @default.
- W4238956186 hasVolume "3" @default.
- W4238956186 isParatext "false" @default.
- W4238956186 isRetracted "false" @default.
- W4238956186 workType "editorial" @default.